Global North America Patient Derived Xenograft (PDX) Models Market Size, Share, Growth Analysis Report - Forecast 2034

North America Patient Derived Xenograft (PDX) Models Industry Prospective:

The global north america patient derived xenograft (PDX) models market size was worth around USD 104.71 Million in 2024 and is predicted to grow to around USD 555.53 Million by 2034 with a compound annual growth rate (CAGR) of roughly 18.16% between 2025 and 2034. The report analyzes the global north america patient derived xenograft (PDX) models market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the north america patient derived xenograft (PDX) models industry.Request Free Sample

The report analyzes the North America Patient Derived Xenograft (PDX) Model's market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the North America Patient Derived Xenograft (PDX) Models industry.    

North America Patient Derived Xenograft (PDX) Models Market: Overview

Tumor tissue or patient cells are injected into humanized or immune-deficient mice to create patient-derived xenografts (PDX), which are cancer models. The best study model for assessing effectiveness is the PDX model, which replicates the biology of human tumors and allows the disease to grow naturally. In patient-derived xenograft (PDX) animal models, fresh human tumor tissues are surgically removed from patients or other patients and then promptly transplanted into immunodeficient mice. Serial cancer transfers between mice might keep some genes expressed in tumors. With the use of these models, it is feasible to study the biology and pharmacology of tumors while doing in vitro cell culture studies without the need for physical handling. and are commonly employed in the creation of pharmaceuticals, clinical trials, and personalized cancer treatment. When compared to genetically modified animals and cell line-derived xenograft models, PDX models show higher predictive values for clinical outcomes.

Key Insights

• As per the analysis shared by our research analyst, the global north america patient derived xenograft (PDX) models market is estimated to grow annually at a CAGR of around 18.16% over the forecast period (2025-2034).
• Regarding revenue, the global north america patient derived xenograft (PDX) models market size was valued at around USD 104.71 Million in 2024 and is projected to reach USD 555.53 Million by 2034.
• The north america patient derived xenograft (PDX) models market is projected to grow at a significant rate due to increasing prevalence of cancer, growing investment in oncology R&D and personalized medicine, and the rising demand for more predictive preclinical models to enhance drug development success rates.
• Based on Type, the Mice Models segment is expected to lead the global market.
• On the basis of Tumor Type, the Gastrointestinal Tumor Models segment is growing at a high rate and will continue to dominate the global market.
• Based on the Application, the Preclinical Drug Development segment is projected to swipe the largest market share.
• By Technique, the Heterotopic Implantation segment is expected to dominate the global market.
• In terms of End User, the Academic and Research Organizations segment is anticipated to command the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

North America Patient Derived Xenograft (PDX) Models Market: Growth Drivers

The increasing demand for personalized medicine drives the market growth

To deliver customized medication and care based on individual and genetic differences, personalized medicine involves creating custom medications. Animal models are used to create these medications. In this procedure, human tissues are added to immunodeficient mice, and the disease expression is tracked. Then, to create appropriate or tailored medications, the model with pharmaceuticals and gene therapies is used to identify the best treatment. The creation of medicines for important diseases like cancer has garnered a lot of interest.

Currently, cancer places a heavy load on the global healthcare system. According to the American Cancer Society, cancer fatalities and new cases are anticipated to rise in 2022. The number of newly diagnosed cases of cancer is predicted to reach 1.9 million, and there will be 609,360 cancer deaths in the US in 2022. Strategies are being created to combat the increased incidence of cancer and provide patients with effective therapies in vivo and in vitro. The discovery of PDX models, which have a high predictive capacity for the effectiveness of both conventional and cutting-edge anti-cancer treatments, represents a significant step in this area. These animals are commonly employed in preclinical investigations due to their ease. Thus, this is expected to drive the North American PDX model market growth during the forecast period.

North America Patient Derived Xenograft (PDX) Models Market: Restraints

High cost and time-intensive processes might be hampering the market expansion

PDX model development and maintenance may be costly and time-consuming. Complex processes are used throughout the process, including the collection of tumor tissue, the creation of animal models, and the upkeep of the mice colonies. As a result, establishing and maintaining PDX models may be quite expensive and time-consuming, especially for smaller research institutes. Thus, this is expected to act as a major restraint for the North America patient derived xenograft industry growth over the forecast period.

North America Patient Derived Xenograft (PDX) Models Market: Opportunities

The increasing partnership offers a lucrative opportunity for the market growth

The increasing partnership in the industry is expected to provide a potential opportunity for market revenue growth over the forecast period. For instance, in July 2022, GemPharmatech announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The goal of this agreement is to speed up the development of novel therapeutics for a variety of unmet medical needs, particularly in immuno-oncology. Charles River will create foundation colonies, and starting in 2023, the models will be sold commercially.

Under the terms of the agreement, GemPharmatech will give Charles River access to its exclusive range of NCG derivative products for use in breeding and distribution in specified markets. One of the most complete portfolios of immunodeficient research models is the NCG derivative product line. The use of human peripheral blood mononuclear cells (PBMC), human hematopoietic stem cells (HSC), patient-derived xenograft (PDX), and immune system reconstitution using NCG-based mice is appropriate for preclinical cancer immunotherapy research. Currently, Charles River is the only distributor of NCG mice in North America, and this partnership expands the range of NCG models available to Charles River. Thus, this is expected to flourish the North America patient derived xenograft market growth.

North America Patient Derived Xenograft (PDX) Models Market: Challenges

The development of alternative techniques acts as a major challenge to the market

Alternative preclinical models, including organoids and humanized mouse models, are constantly being researched and developed by scientists since they may be more advantageous than PDX models in some situations. The expansion of the PDX market can be hampered by the availability of various substitute models. Thus, acting as a major challenge to market growth.

North America Patient Derived Xenograft (PDX) Models Market: Segmentation

North America Patient Derived Xenograft (PDX) Models industry is segmented based on Type, Tumor Type, Application, Technique, End User, and region.

Based on the tumor type, the North American PDX models market is bifurcated into lung cancer, pancreatic cancer, prostate cancer, breast cancer, and others. The breast cancer segment is expected to dominate the market over the forecast period. The segment growth is attributed to the growing prevalence of cancer in the US. For instance, according to the data given by the American Cancer Society, except for skin cancers, breast cancer is the most prevalent cancer in women in the US. 30% (or 1 in 3) of all new cases of female cancer each year are caused by it. In 2023, there will be 297,790 new instances of invasive breast cancer in women. Therefore, these facts support the segment expansion during the forecast period.

Based on the model type, the North American PDX models industry is segmented into mice and rats. The mice model segment is expected to capture a significant market share over the forecast period. The most widely used animal model for studying human disease and health is the mouse. A compact, practical, and effective solution is the mouse. More than a century of research on mice has resulted in a wealth of knowledge on their physiology, anatomy, and genes. The mice's short gestation period and long lifespan (one mouse year is roughly comparable to 30 human years) reduce the cost, duration, and amount of space required for the study. The aforementioned benefits & factors fuel the segment's expansion.

Based on the end user, the North America patient derived xenograft market is divided into pharmaceutical and biopharmaceutical companies, academic & research institutes, and CROs & CDMOs. The CROs & CDMOs segment is expected to grow at the fastest rate over the forecast period. This market will expand as a result of increased operations such as mergers and acquisitions, service expansion, and pharmaceutical and biopharmaceutical businesses outsourcing their research efforts. For instance, in 2019 Envigo purchased the assets of the Research Models Business Unit of Horizon Discovery Unit Plc.

By Application, the global north america patient derived xenograft (PDX) models market is split into Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research, Biomarker Analysis, Oncology Research.

In terms of Technique, the global north america patient derived xenograft (PDX) models market is categorized into Heterotopic Implantation, Orthotropic Implantation.

North America Patient Derived Xenograft (PDX) Models Market: Report Scope

North America Patient Derived Xenograft: Regional Analysis

The US is expected to dominate the market over the forecast period

The US is expected to dominate the North America PDX models market over the forecast period. A few of the reasons propelling the growth of the patient-derived xenograft models market in the US include key product releases, high concentrations of market participants or manufacturer's presence, acquisitions & alliances among leading companies, and an increase in cancer cases. For instance, KIYATEC submitted fresh clinical correlation data to the American Association for Cancer Research in March 2024. With published data showing how predicted response correlates with clinical outcomes, KIYATEC's 3D Predict and KIYA-PREDICT clinical and preclinical technology platforms are pioneers in functional precision oncology. Applications in diverse tumor types, responses to immunotherapy, and ex vivo use of PDX for preclinical drug development are among the topics covered in the six abstracts that were approved for presentation at the conference. Therefore, this is expected to drive market growth in the region.

North America Patient Derived Xenograft (PDX) Models Market: Competitive Analysis

The global north america patient derived xenograft (PDX) models market is dominated by players like:

• Crown Bioscience Inc. (U.S.)
• THE JACKSON LABORATORY (U.S.)
• Champions Oncology Inc
• (U.S.)
• Charles River Laboratories (U.S.)
• Wuxi AppTec (China)
• Oncodesign (Canada)
• Aragen Bioscience (India)
• Biocytogen (U.S.)
• Bioduro (U.S.)
• Creative Animodel (U.S.)
• Covance Inc. (U.S.)
• EPO Berlin-Buch GmbH (Germany)
• EUROPDX. (Belgium)
• Explora BioLabs (U.S.)
• Hera BioLabs (U.S.)
• Horizon discovery Ltd. (U.K.)
• Pharmatest Services (Finland)
• Urospehere SAS (Cyprus)
• Xentech (France)
• Xenopat (France)

The global north america patient derived xenograft (PDX) models market is segmented as follows;

By Type

• Mice Models
• Rat Models

By Tumor Type

• Gastrointestinal Tumor Models
• Lung Tumor Models
• Haematological Tumor Models
• Gynecological Tumor Models
• Respiratory Tumor Models
• Urological Tumor Models
• Others

By Application

• Preclinical Drug Development
• Precision Medicine
• Co-Clinical Trials
• Basic Cancer Research
• Biomarker Analysis
• Oncology Research

By Technique

• Heterotopic Implantation
• Orthotropic Implantation

By End User

• Academic and Research Organizations
• Contract Research Organizations
• Pharmaceutical and Biotechnological Companies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America